Effect of Weight Loss Medications on Hepatic Steatosis and Steatohepatitis: A Systematic Review

Non-alcoholic fatty liver disease (NAFLD) is a common comorbidity in individuals with obesity. Although multiple pharmacotherapeutics are in development, currently there are limited strategies specifically targeting NAFLD. This systematic review summarizes the existing literature on hepatic effects of medications used for weight loss. Glucagon-like peptide 1 (GLP-1) agonists are the best-studied in this regard, and evidence consistently demonstrates reduction in liver fat content, sometimes accompanied by improvements in histological features of steatohepatitis and reductions in serum markers of hepatic injury such as alanine aminotransferase (ALT). It remains unclear whether these benefits are independent of the weight loss caused by these agents. Literature is limited regarding effects of orlistat, but a small number of reports suggest that orlistat reduces liver fat content and improves histologic features of NASH, benefits which may also be driven primarily by weight loss. A sizeable body of literature on hepatic effects of metformin yields mixed results, with a probability of modest benefit, but no consistent signal for strong benefit. There are insufficient data on hepatic effects of topiramate, phentermine, naltrexone, bupropion, and lorcaserin. Finally, a few studies to date suggest that sodium-glucose co-transporter-2 (SGLT2) inhibitors may reduce liver fat content and cause modest reductions in ALT, but further study is needed to better characterize these effects. B...
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research

Related Links:

Condition:   Non-alcoholic Fatty Liver Disease (NAFLD) Interventions:   Drug: Metabolic Cofactor Supplementation;   Drug: Sorbitol Sponsors:   ScandiBio Therapeutics AB;   Koç University;   Koç University Hospital;   Göteborg University;   Sahlgrenska University Hospital, Sweden;   KTH Royal Institute of Technology;   University of Helsinki;   Helsinki University Central Hospital;   Monitor CRO Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conclusions: The prevalence of suspected NAFLD continues to increase in Korean adolescents.Abbreviations: ALT, alanine aminotransferase; BMI, body mass index; KNHANES, Korea National Health and Nutrition Examination Survey; NAFLD, non-alcoholic fatty liver disease. PMID: 32223545 [PubMed - as supplied by publisher]
Source: Paediatrics and international child health - Category: Pediatrics Tags: Paediatr Int Child Health Source Type: research
AbstractIntroductionInsulin resistance (IR) plays a central role in pathogenesis of nonalcoholic steatohepatitis (NASH). The aim of this study was to correlate histopathological grading and IR in overweight/obese patients with NASH as compared with lean NASH.MethodsPatients with NASH who underwent liver biopsy between January 2012 and December 2012 were included. Anthropometric, clinical, and biochemical features, necro-inflammatory grades, and fibrosis stage on liver biopsies were scored according to Brunt and non-alcoholic fatty liver disease (NAFLD) activity score (NAS).ResultsOf 42 patients, 33 (78.6%) had body mass in...
Source: Indian Journal of Gastroenterology - Category: Gastroenterology Source Type: research
Publication date: Available online 23 March 2020Source: Pharmacological ResearchAuthor(s): Helda Tutunchi, Alireza Ostadrahimi, Maryam Saghafi-Asl, Mohammad-Javad Hosseinzadeh-Attar, Abolhasan Shakeri, Mohammad Asghari-Jafarabadi, Neda Roshanravan, Nazila Farrin, Mohammad Naemi, Milad Hasankhani
Source: Pharmacological Research - Category: Drugs & Pharmacology Source Type: research
Non-alcoholic fatty liver disease (NAFLD) is considered the hepatic manifestation of the metabolic syndrome, as it is closely related to obesity, dyslipidemia and insulin resistance [1]. Accordingly, the prevalence of NAFLD and non-alcoholic steatohepatitis (NASH), NAFLD ’s later evolutive stage, are increasing at the same pace as obesity becomes a global epidemic. In fact, today, NAFLD is considered to be the number one cause of chronic liver disease worldwide [2-4]. As no specific drugs have yet been approved for NAFLD, at present, the only effective treatment i s weight loss through diet and exercise.
Source: Surgery for Obesity and Related Diseases - Category: Surgery Authors: Tags: Review articles Source Type: research
Non-alcoholic fatty liver disease (NAFLD) is increasing in prevalence in concert with the global epidemic of obesity and is being diagnosed at increasingly younger ages. The unique histological features and early presentation of disease in pediatrics suggest that children and adults may differ in regards to eitopathogenesis, with children displaying a larger vulnerability to genetic and environmental factors. Of significant relevance to pediatrics, in utero and perinatal stressors may alter the lifelong health trajectory of a child, increasing the risk of NAFLD and other cardiometabolic diseases.
Source: Gastroenterology - Category: Gastroenterology Authors: Source Type: research
Source: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy - Category: Endocrinology Tags: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Source Type: research
AbstractBackground and AimIn patients with liver disease, etiology and body mass index (BMI) affects controlled attenuation parameter (CAP) assessment using FibroScan. We aimed to assess the performance characteristics of CAP for hepatic steatosis in patients with non-alcoholic fatty liver disease (NAFLD) stratified into obese (BMI ≥ 30 kg/m2) and non-obese (BMI
Source: Indian Journal of Gastroenterology - Category: Gastroenterology Source Type: research
Authors: Karolczak D, Seget M, Bajerska J, Błaszczyk A, Drzymała-Czyż S, Walkowiak J, Marszałek A Abstract Green tea contains many polyphenolic constitutes, which might prevent non-alcoholic fatty liver disease (NAFLD). We aimed to investigate whether green tea extract (GTE) given at doses reflecting habitual consumption of green tea beverages prevents development of NAFLD in rats fed a high-fat diet (HFD). Twenty-four male Wistar rats were randomly divided into four equal groups (two study and two control groups). The study groups received a HFD (approximately 50% energy from fat), enriched with 1.1% and 2.0% ...
Source: Polish Journal of Pathology - Category: Pathology Tags: Pol J Pathol Source Type: research
AbstractThe growing burden of non-alcoholic fatty liver disease (NAFLD) parallels the increasing prevalence of obesity in Asia. The overall prevalence of NAFLD in Asia is now estimated to be 29.6% and may have surpassed that in Western populations. NAFLD increases with increasing age and is closely associated with metabolic syndrome. Ethnic differences exist in the prevalence of NAFLD, but the underlying factors are unclear. There were initial concerns about lean NAFLD being associated with more severe liver disease and increased mortality, but subsequent studies suggested otherwise. Only some NAFLD patients progress to de...
Source: Indian Journal of Gastroenterology - Category: Gastroenterology Source Type: research
More News: Adipex | Alcoholism | Alli | Bupropion | Eating Disorders & Weight Management | Endocrinology | Fatty Liver Disease (FLD) | Fortamet | Liver | Liver Disease | Metformin | Non-alcoholic Fatty Liver Diseases (NAFLD) | Nutrition | Obesity | Phentermine | SGLT2 Inhibitors | Sodium | Sports Medicine | Study | Topamax | Urology & Nephrology | Weight Loss | Wellbutrin | Xenical